- Home
- ATAI vs EHAB Comparison
ATAI vs EHAB Comparison
Compare ATAI & EHAB Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- ATAI
- EHAB
- Stock Information
- Founded
- ATAI 2018
- EHAB 2014
- Country
- ATAI Germany
- EHAB United States
- Employees
- ATAI N/A
- EHAB N/A
- Industry
- ATAI Biotechnology: Pharmaceutical Preparations
- EHAB Hospital/Nursing Management
- Sector
- ATAI Health Care
- EHAB Health Care
- Exchange
- ATAI Nasdaq
- EHAB Nasdaq
- Market Cap
- ATAI 444.7M
- EHAB 401.6M
- IPO Year
- ATAI 2021
- EHAB N/A
- Fundamental
- Price
- ATAI $2.48
- EHAB $9.30
- Analyst Decision
- ATAI Strong Buy
- EHAB Hold
- Analyst Count
- ATAI 3
- EHAB 3
- Target Price
- ATAI $10.50
- EHAB $8.50
- AVG Volume (30 Days)
- ATAI 2.7M
- EHAB 422.7K
- Earning Date
- ATAI 08-12-2025
- EHAB 08-05-2025
- Dividend Yield
- ATAI N/A
- EHAB N/A
- EPS Growth
- ATAI N/A
- EHAB N/A
- EPS
- ATAI N/A
- EHAB N/A
- Revenue
- ATAI $1,863,000.00
- EHAB $1,032,300,000.00
- Revenue This Year
- ATAI $554.22
- EHAB $4.66
- Revenue Next Year
- ATAI N/A
- EHAB $4.99
- P/E Ratio
- ATAI N/A
- EHAB N/A
- Revenue Growth
- ATAI 572.56
- EHAB N/A
- 52 Week Low
- ATAI $1.03
- EHAB $6.85
- 52 Week High
- ATAI $2.64
- EHAB $10.91
- Technical
- Relative Strength Index (RSI)
- ATAI 66.50
- EHAB 36.86
- Support Level
- ATAI $2.06
- EHAB $10.65
- Resistance Level
- ATAI $2.55
- EHAB $10.91
- Average True Range (ATR)
- ATAI 0.20
- EHAB 0.31
- MACD
- ATAI -0.02
- EHAB -0.21
- Stochastic Oscillator
- ATAI 72.41
- EHAB 1.88
About ATAI ATAI Life Sciences N.V.
ATAI Life Sciences NV is a clinical-stage biopharmaceutical company on a mission to develop effective mental health treatments to transform patient outcomes. The company's pipeline of psychedelic-based therapies includes VLS-01 (buccal film DMT) for treatment-resistant depression (TRD) and EMP-01 (oral R-MDMA) for social anxiety disorder. It is also advancing a drug discovery program to identify novel, non-hallucinogenic 5-HT2AR agonists for TRD.
About EHAB Enhabit Inc.
Enhabit Inc provides home health and hospice services in the United States. Its reportable segments are Home Health and Hospice. The Home Health segment includes a comprehensive range of Medicare-certified home nursing services to adult patients in need of care. These services include, among others, skilled nursing, physical, occupational, and speech therapy, medical social work, and home health aide services. The Hospice segment focuses on the quality of life for patients who are experiencing an advanced, life-limiting illness while treating the person and symptoms of the disease, rather than the disease itself. The company generates a majority of its revenue from the Home Health segment.